Briana Contreras

Briana Contreras

Briana Contreras is an editor at Managed Healthcare Executive, where she covers the clinical, business and policy developments that matter to payers and health plan leaders, with an additional focus in multiple clinical spaces. Her reporting spans from new cancer therapies and clinical trial data to drug affordability and biosimilars, pharmacy benefit management (PBM) and health plan operations, giving healthcare executives clear context on how new evidence can affect coverage and care decisions.

Experience:

Before joining MHE in 2019, Briana was a reporter at The Morning Journal in Lorain, Ohio, west of Cleveland, where she covered local government, community news and the issues affecting residents across Lorain and Erie counties. She reported on city council, downtown redevelopment, library and school projects, local business, nonprofits and breaking news in Elyria, Lorain and nearby communities.

Education:

Briana graduated from Cleveland State University with a B.A. in Journalism and Promotional Communication.

Articles by Briana Contreras

PEPFAR, having invested $100 billion and saved 25 million lives in the global fight against HIV/AIDS, faces Congressional hurdles in its reauthorization due to abortion debates. Despite widespread support and no evidence of abortion-related activities, the legislative process is at a standstill. Members of PEPFAR and authors of a recent editorial stress the significance of PEPFAR and advocate for integrating behavioral and social science into healthcare programs to achieve UNAIDS targets and address barriers in HIV/AIDS testing and treatment.

Coffee, rich in polyphenolic compounds like chlorogenic acid (CGA), caffeic acid (CAA), cafestol, melanoidins and trigonelline, has been recognized as a dominant source of CGA in various studies. Previous studies suggest that CGA in coffee can positively impact blood pressure, lipid profile, glycemia and insulin resistance.

Briana Contreras, an editor with Managed Healthcare Executive, spoke with Harsha Rajasimha, MD, founder and executive chairman of IndoUSrare, in this month's episode of Tuning in to the C-Suite podcast. The conversation was about how the disparity in diversity and ethnicity in rare disease clinical trials in the U.S. has led to gaps in understanding diseases and conditions, jeopardizing universal health, and increasing the economic burden of healthcare.